Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

personalised medicines

Mtech Access certified as a NICE META tool facilitating organisation

Mtech Access are now a certified NICE META Tool facilitating organisation, with three experts having passed the NICE assessment

Mtech Access

- PMLiVE

New £5m project launched to bring Alzheimer’s blood tests to the NHS

Blood tests for the condition could become available on the NHS within five years

- PMLiVE

UK antibiotic subscription model found by OHE as key to supporting investment

The OHE report offers valuable insights into investor views of the subscription model

- PMLiVE

Novartis’ Cosentyx recommended by NICE for hidradenitis suppurativa

At least 200,000 people in the UK are affected by the inflammatory skin disease

- PMLiVE

Life sciences leaders warn against ‘unworkable’ changes to UK medicines scheme

The scheme could impact UK life sciences and NHS patient access to medicines

- PMLiVE

Health and Social Care Committee report on vaccination calls for urgent action in the UK

In England, coverage for childhood immunisations was below target in 2021 and 2022

- PMLiVE

UK life sciences sector sees substantial drop in international investment

The estimated value of inward foreign direct investment fell from £1.9bn in 2021 to £1bn in 2022

- PMLiVE

Bristol Myers Squibb’s Sotyktu recommended by NICE for plaque psoriasis

An estimated 1.8 million people in the UK are affected by some form of the condition

- PMLiVE

MHRA to introduce new UK clinical trials framework

The changes will aim to make it easier to gain approval and to run clinical trials in the UK

- PMLiVE

ABPI welcomes new NHS research guidance for integrated care systems

Included in the proposals are calls for a fixed rebate rate of 6.88% on all eligible NHS medicine sales to be paid by the industry

- PMLiVE

Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches

This is only the eighth time in the past 40 years that ABPI has issued such a significant sanction

- PMLiVE

AstraZeneca’s Evusheld not recommended by NICE for COVID-19 prevention

The agency said there is not enough evidence of the drug’s effectiveness against current variants

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links